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The data presented in this article are related to the research paper
entitled “peroxiredoxin-2 plays a pivotal role as multimodal
cytoprotector in the early phase of pulmonary hypertension”
(Federti et al., 2017) [1]. Data show that the absence of peroxir-
edoxin-2 (Prx2) is associated with increased lung oxidation and
pulmonary vascular endothelial dysfunction. Prx2−/− mice dis-
played activation of the redox-sensitive transcriptional factors, NF-
kB and Nrf2, and increased expression of cytoprotective system
such as heme-oxygenase-1 (HO-1). We also noted increased
expression of both markers of vascular activation and extracellular
matrix remodeling. The administration of the recombinant fusionis an open access article under the CC BY license
/j.freeradbiomed.2017.08.004
e Franceschi).
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E. Federti et al. / Data in Brief 15 (2017) 376–381 377protein PEP Prx2 reduced the activation of NF-kB and Nrf2 and was
paralleled by a decrease in HO-1 and in vascular endothelial
abnormal activation. Prolonged hypoxia was used to trigger pul-
monary artery hypertension (PAH). Prx2−/− precociously devel-
oped PAH compared to wildtype animals.
& 2017 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Health Sciences
ore speciﬁc sub-
ject areaOxidation, peroxiredoxin-2 and pulmonary artery hypertensionype of data Text ﬁle, Figures
ow data was
acquiredImage Quant Las Mini 4000 Digital Imaging System (GE Healthcare Life
Sciences). Densitometric analyses were performed using the ImageQuant TL
software (GE Healthcare Life Sciences).ata format Raw analyzed
xperimental
factorsC57B6/2J as wildtype mice and Prx2−/− micexperimental
featuresProtein expression was analyzed by Western-blotting.
Oxidized proteins were revealed by the Oxyblot Protein Oxidation Detection
Kit (EMD Millipore); MDA pulmonary levels were evaluated by Oxiselect
MDA Immunoblot kit (GE Healthcare).ata source
locationDept. of Medicine, LURM, Policlinico GB Rossi, University of Verona and AOUI
Verona; Verona; Italyata accessibility Data are available with this articleD
Value of the data
 Our data show that the absence of Prx2 is associated with increased lung oxidation and abnormal
pulmonary vascular leakage.
 Treatment with fusion protein PEP Prx2 prevents the activation of redox related transcriptional
factors and modulates anti-oxidant systems in both wildtype and Prx2−/− mice.
 PEP Prx2 signiﬁcantly reduces protein oxidation in lung from exposed to prolonged hypoxia used
to trigger pulmonary artery hypertension.1. Data
Data show increased lung oxidation (Fig. 1A) and abnormal pulmonary vascular leakage in the
absence of Prx2 (Fig. 1B). This was paralleled by the activation of redox-sensitive transcriptional
factors NF-kB and Nrf2 in lung from Prx2−/− compared to wildtype animals (Fig. 2A). Indeed, in Prx2−/
− we observed (i) increased expression of heme-oxygenase 1 (HO-1), a Nrf2 related cytoprotective
system; (ii) markers of vascular endothelial activation such as endothelin-1 (ET-1) and vascular cell
adhesion molecule -1 (VCAM-1) and (iii) marker of extracellular matrix remodeling as the platelet
growth factor- B (PDGF-B) that has been recently function linked to the development of pulmonary
artery hypertension (Fig. 2B). To verify the role of Prx2 as important anti-oxidant system in pul-
monary homeostasis, we administrated the recombinant fusion protein PEP Prx2 at the dosage of
3 mg/Kg/d ip or vehicle for 4 weeks [1–3]. As shown in Fig. 2, PEP Prx2 signiﬁcantly reduced both
Fig. 1. A. 10 μg of soluble proteins of lung homogenate were tested for MDA-protein adducts. Quantiﬁcation of band area was
performed by densitometry and expressed as % of WT. The data are presented as means 7 SD of at least three independent
experiments; statistically signiﬁcant differences were determined by Student's t-test. *p o 0.05. B. Upper panel. BAL protein
content fromwildtype (WT) and Prx2−/−mice under normoxic condition. Data are presented as means7 SD (n ¼ 6; *p o 0.05
compared to WT mice). Lower panel. BAL leukocyte content from wildtype (WT) and Prx2−/− mice under normoxic condition.
Data are presented as means 7 SD (n ¼ 6; *p o 0.05 compared to WT mice).
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markers of vascular endothelial activation or extracellular matrix remodeling.
Using prolonged hypoxia to trigger pulmonary artery hypertension, we observed severe lung
pathologic damage and the precocious development of pulmonary artery hypertension in Prx2−/−
mice compared to wildtype animals [4–6]. This was associated with (i) marked activation of redox-
related transcriptional factors; (ii) severe endoplasmic-reticulum stress with activation of the
unfolded protein response (UPR) system; and (iii) activation of autophagy [1].
PEP Prx2 treatment prevented the hypoxia induced protein oxidation in mice exposed to pro-
longed hypoxia (7 days; Fig. 3A) and reduced the hypoxia induced increased expression of HO-1 in
both mouse strains exposed to 3 days hypoxia (Fig. 3B). Collectively, these data indicate the important
role of Prx2 in lung homeostasis against hypoxia, a known trigger of lung injury.2. Experimental design, materials and methods
2.1. MDA assay
MDA was determined as previously reported [7,8].2.2. Measurement of BAL protein content
2.2.1. Bronchoalveolar lavage assay
Bronchoalveolar lavage (BAL) ﬂuids were collected and cellular contents were recovered by cen-
trifugation and counted by microcytometry as previously reported [6,9].
Fig. 2. A. Immunoblot analysis with speciﬁc antibodies against phospho-Nrf2 (P-Nrf2), Nrf2 phospho-NF-kB (P-NF-kB) and NF-
kB of lung fromwildtype (WT) and Prx2−/−mice under normoxic condition. One representative gel from six with similar results
is presented. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of phospho-NF-kB (P-NF-kB), NF-k,
phospho-Nrf2 (P-Nrf2) and Nrf2 of lung from wildtype (WT) and Prx2−/− mice under normoxic condition treated with either
vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). Data are shown as means 7 SD (n ¼ 6). *p o 0.05
compared to wildtype; °p o 005 compared to vehicle treated mice. B. Immunoblot analysis with speciﬁc antibodies against
heme-oxygenase 1 (HO-1), endothelin-1 (ET-1), vascular cell adhesion molecule-1 (VCAM-1), under normoxic condition
treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2). One representative gel from six
with similar results is presented. Right panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of heme-oxy-
genase 1 (HO-1), endothelin-1 (ET-1), vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth factor-B (PDGF-B)
of lung from wildtype (WT) and Prx2−/− mice under normoxic condition treated with either vehicle or penetrating peptide
fusion protein peroxiredoxin-2 (PEP Prx2). Data are shown as means 7 SD (n ¼ 6). *p o 0.05 compared to wildtype; °p o
0.05 compared to vehicle treated mice.
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Frozen lung from each studied group were homogenized and lysed with iced lyses buffer as
previously described [3,10,11]. Gels were transferred to nitrocellulose membranes for immuno-blot
analysis with speciﬁc antibody: anti-NFkB-phospho-S536 (93H1) (Cell Signaling Technology, Leiden,
NL); anti-NFkB p65 (C22B4) (Cell Signaling Technology, Leiden, NL); anti-Nrf2-phospho-S40 (Clone
EP1809Y, AbCam, Cambridge, UK); anti-Nrf2 (AbCam, Cambridge, UK); anti-Heme Oxygenase-1 (HO-
1) (Santa Cruz Biotechnology, Heidelberg, Germany), anti-Endothelin-1 (ET-1) (Santa Cruz Bio-
technology, Heidelberg, Germany); anti-VCAM-1 (R and D Systems, Minneapolis, MN, USA); anti-
PDGF-B (AbCam, Cambridge, UK); anti-GAPDH (Sigma Aldrich, Saint Louis, MO, USA) was used as
loading control. Images were acquired using Image Quant Las Mini 4000 Digital Imaging System (GE
Healthcare Life Sciences). Densitometric analyses were performed using the ImageQuant TL software
(GE Healthcare Life Sciences) [11].
Fig. 3. A. The carbonylated proteins (1 ug) from lung of Prx2−/− mice under normoxic condition or exposed to 7 days (7D)
hypoxia/reoxygenation stress (H/R) treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP
Prx2) at the dosage of 3 mg/Kg/d ip or vehicle for 4 weeks before and during hypoxia (8% oxygen for 7 days). Right panel.
Quantiﬁcation of band area was performed by densitometry and expressed as % of Prx2 under normoxia. The data are pre-
sented as means 7 SD of at least three independent experiments; ^p o 0.05 compared to Prx2−/− normoxic mice; °p o 005
compared to vehicle treated mice. (n ¼ 3). B. Immunoblot analysis with speciﬁc antibodies against heme-oxygenase-1 (HO-1)
of lung from wildtype (WT) and Prx2−/− mice under normoxic condition or exposed to 3 days (3D) hypoxia/reoxygenation
stress (H/R) treated with either vehicle or penetrating peptide fusion protein peroxiredoxin-2 (PEP Prx2) at the dosage of 3 mg/
Kg/d ip or vehicle for 4 weeks before and during hypoxia (8% oxygen for 3 days). One representative gel from ﬁve with similar
results is presented. Lower panel. Relative quantiﬁcation of immunoreactivity (DU: Density Units) of heme-oxygenase 1 of lung
fromwildtype (WT) and Prx2−/− mice under normoxic condition or exposed to 3 days (3D) hypoxia/reoxygenation stress (H/R)
treated with either vehicle or PEP Prx2. Data are presented as means 7 SD of at least ﬁve independent experiments; *p o 0.05
compared to wildtype; ^p o 0.05 compared to Prx2−/− normoxic mice; °p o 005 compared to vehicle treated mice. (n ¼ 5).
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Oxidized proteins were revealed by the Oxyblot Protein Oxidation Detection Kit (EMD Millipore).
In brief, the soluble protein extracts were derivatized to 2,4-dinitrophenylhydrazone (DNP) and 1 µg
was loaded on 12% SDS-PAGE, blotted and incubated with an anti-DNP antibody, followed by an HRP
conjugated secondary antibody. The bound activity was revealed by ECL (GE Healthcare). Oxidized
proteins were revealed by the Oxyblot Protein Oxidation Detection Kit (EMD Millipore). In brief, the
soluble protein extracts were derivatized to 2,4-dinitrophenylhydrazone (DNP) and 1 ug was loaded
on 12% SDS-PAGE, blotted and incubated with an anti-DNP antibody, followed by an HRP conjugated
secondary antibody. The bound activity was revealed by ECL (GE Healthcare) [12–14].2.2.4. Generation of recombinant-PEP Prx2 fusion protein (PEP Prx2)
The fusion protein PEP Prx2 was generated as previously reported [2,3].Acknowledgements
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